Drugs / TQB3912
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05997342 | Aug 2023 → May 2025 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06851442 | May → Nov 2025 | breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3912 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06851442 ↗ |
| Modality | Small molecule | “TQB3912 is a small molecule Phosphorylated protein kinase inhibitor.” NCT05997342 ↗ |